Summary
Evaluation cannot be completed against the provided FDA-approved prescribing information because the response claims only about FDA approval date and historical indication expansion, which are not present in the supplied label excerpts. As a result, the label support/contradiction status of these claims cannot be verified from the provided prescribing information.
Category Scores
Accurate Statements
None (no claim could be verified as supported by the provided label excerpts).
Not verifiable: the provided excerpts do not include approval dates or historical approval timeline; they include current indications and dosing.
Unsupported Statements
Ofev (nintedanib) was approved in the United States on October 15, 2014.
The supplied label excerpts do not contain FDA approval dates.
Ofev (nintedanib) was approved in the United States on October 15, 2014 for the treatment of idiopathic pulmonary fibrosis (IPF).
Approval date and the linkage to that date are not stated in the supplied label excerpts; only current indication language is provided.
Ofev (nintedanib) was approved in the United States on October 15, 2014 for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype.
The supplied label excerpts include the indication wording for chronic fibrosing ILDs with a progressive phenotype, but do not provide an approval date for it.
Ofev (nintedanib) gained additional indications over time, including use in non-IPF progressive fibrosing interstitial lung disease (PF-ILD).
The provided label excerpts include an indication for chronic fibrosing ILDs with a progressive phenotype, but do not describe historical indication expansions or specifically state 'gained additional indications over time' or 'PF-ILD'.
Ofev (nintedanib) gained additional indications over time, including use in interstitial lung disease associated with systemic sclerosis (SSc-ILD).
The provided label excerpts include an indication for systemic sclerosis-associated ILD, but do not describe historical indication expansions or explicitly reference 'gained additional indications over time'.
Contradictions
Important Omissions
No information about dosing/administration, contraindications, boxed warnings, or safety monitoring was provided/assessed; however the user claims are about approval timing/indication history, which are not covered in the supplied excerpts.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claims evaluated concern regulatory approval dates and historical indication expansion rather than specific dosing or safety actions. While not verifiable from the provided label excerpts, these statements do not directly instruct a treatment action.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Verifiable from Provided Label Excerpts
Primary Issue
Claims about FDA approval dates and historical addition of indications are not present in the provided prescribing information excerpts, so on-label support cannot be established.
Suggested Improvement
Limit claims to language explicitly present in the provided label sections (e.g., current indications in Sections 1.1–1.3) and avoid asserting specific approval dates or historical approval/label-expansion timelines unless that information is included in the supplied label text.